...
首页> 外文期刊>Journal of Surgical Research: Clinical and Laboratory Investigation >Serotonin receptor blockade increases food intake and body weight after total gastrectomy in rats.
【24h】

Serotonin receptor blockade increases food intake and body weight after total gastrectomy in rats.

机译:在大鼠全胃切除术后,血清素受体阻滞剂增加食物摄入量和体重。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: Total gastrectomy often results in early satiety and loss of body weight. Serotonin inhibits food intake, and postprandial serotonin release is increased after total gastrectomy. Serotonin might contribute to early satiety and loss of body weight after total gastrectomy. METHODS AND MATERIALS: Food intake and body weight were investigated with an automated recording system in gastrectomized rats 1-12 months postoperatively. Rats were treated with metergoline, a 5-hydroxytryptamine (5-HT)(1/2) receptor antagonist, two different 5-HT(3) receptor antagonists, a combination of metergoline and devazepide, a cholecystokinin (CCK) a receptor antagonist, or vehicle. In addition, metergoline or vehicle was applied continuously by an intraperitoneal osmotic minipump for 7, 28, or 84 days after total gastrectomy. RESULTS: Metergoline treatment resulted in a dose-dependent increase in food intake in gastrectomized rats. 5-HT(3) receptor antagonist treatment had no effect, and devazepide in addition to metergoline did not further stimulate food intake. Metergoline increased food intake at 1, 3, and 6 months postoperatively by up to 45% (24-h cumulative food intake [FI], 6 months: vehicle 3.83 +/- 0.10, metergoline 5.52 +/- 0.15 g/100 g body weight (BW), P < 0.0001). Chronic metergoline treatment for 7, 28, or 84 days significantly increased food intake after total gastrectomy compared to vehicle treatment (FI 7 days: vehicle 30.83 +/- 0.71, metergoline 36.27 +/- 0.85 g/100 g BW; P < 0.0002; average weekly FI during 28 days; vehicle 31.23 +/- 0.22, metergoline 36.83 +/- 0.33 g/100 g BW, P < 0.0001; average weekly FI during 84 days: vehicle 33.02 +/- 0.59, metergoline 35.07 +/- 0.48 g/100g BW, P < 0.008), and there was a significant body weight increase compared to vehicle treatment (7 days: DeltaBW vehicle -0.7 +/- 1.2 g vs DeltaBW metergoline 9.0 +/- 2.1 g, P < 0.001; 28 days: DeltaBW vehicle 0.3 +/- 2.2 vs DeltaBW metergoline 13.0 +/- 2.3, P < 0.001; 84 days: DeltaBW vehicle 25.7 +/- 10.2 vs DeltaBW metergoline 49.5 +/- 7.2, P < 0.04). Treatment for 84 days resulted in a significant body weight gain, while vehicle treatment had no effect (vehicle: 438 +/- 11 g vs 464 +/- 12 g, P < 0.2, n.s.; metergoline: 448 +/- 9 g vs 498 +/- 10 g, P < 0.007). CONCLUSIONS: Inhibition of food intake by serotonin might contribute to early satiety and loss of body weight after total gastrectomy.
机译:背景:全胃切除术通常会导致早期饱腹感和体重减轻。 5-羟色胺抑制食物摄入,全胃切除术后餐后5-羟色胺释放增加。全胃切除术后,血清素可能有助于早期饱腹感和体重减轻。方法和材料:采用自动记录系统对术后1-12个月气化过的大鼠进食和体重进行了调查。用美特古林,5-羟色胺(5-HT)(1/2)受体拮抗剂,两种不同的5-HT(3)受体拮抗剂,美特古林和devazepide的组合,胆囊收缩素(CCK)受体拮抗剂对大鼠进行治疗,或车辆。此外,在全胃切除术后的7、28或84天,通过腹膜内渗透微型泵连续施用美特古林或溶媒。结果:美特古林治疗导致断胃大鼠的食物摄入量呈剂量依赖性增加。 5-HT(3)受体拮抗剂治疗无效,除去甲美戈林之外,脱氮哌肽不能进一步刺激食物摄入。美特高林在术后1、3和6个月的食物摄入量增加了高达45%(24小时累积食物摄入量[FI],6个月:媒介物3.83 +/- 0.10,美特古林5.52 +/- 0.15 g / 100 g身体重量(BW),P <0.0001)。与赋形剂治疗相比,连续7天,28或84天的美戈洛林治疗显着增加了全胃切除后的食物摄入量(FI 7天:赋形剂30.83 +/- 0.71,美他古林36.27 +/- 0.85 g / 100 g BW; P <0.0002; 28天的平均每周FI;媒介31.23 +/- 0.22,美特古啉36.83 +/- 0.33 g / 100 g体重,P <0.0001; 84天的平均每周FI:媒介33.02 +/- 0.59,美特古琳35.07 +/- 0.48 g / 100g BW,P <0.008),并且与媒介物治疗相比有显着的体重增加(7天:DeltaBW媒介物-0.7 +/- 1.2 g,而DeltaBW美特古琳9.0 +/- 2.1 g,P <0.001; 28天:DeltaBW车辆0.3 +/- 2.2相对于DeltaBW米果戈林13.0 +/- 2.3,P <0.001; 84天:DeltaBW车辆25.7 +/- 10.2 vs DeltaBW米果戈林49.5 +/- 7.2,P <0.04)。治疗84天导致体重显着增加,而媒介物治疗无效(车辆:438 +/- 11 g vs 464 +/- 12 g,P <0.2,ns;美特古琳:448 +/- 9 g vs 498 +/- 10 g,P <0.007)。结论:5-羟色胺抑制食物摄入可能会导致全胃切除术后的早期饱腹感和体重减轻。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号